JP2014508138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508138A5 JP2014508138A5 JP2013549850A JP2013549850A JP2014508138A5 JP 2014508138 A5 JP2014508138 A5 JP 2014508138A5 JP 2013549850 A JP2013549850 A JP 2013549850A JP 2013549850 A JP2013549850 A JP 2013549850A JP 2014508138 A5 JP2014508138 A5 JP 2014508138A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- combination
- group
- heparin
- thrombin inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 15
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 12
- 239000012190 activator Substances 0.000 claims 12
- 239000004019 antithrombin Substances 0.000 claims 12
- 239000003868 thrombin inhibitor Substances 0.000 claims 12
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 11
- 210000004185 liver Anatomy 0.000 claims 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 10
- 229920000669 heparin Polymers 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 210000000130 stem cell Anatomy 0.000 claims 7
- 108010007267 Hirudins Proteins 0.000 claims 4
- 102000007625 Hirudins Human genes 0.000 claims 4
- 108010055460 bivalirudin Proteins 0.000 claims 4
- 229960001500 bivalirudin Drugs 0.000 claims 4
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical group C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 claims 4
- 229960001318 fondaparinux Drugs 0.000 claims 4
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims 4
- 229960002897 heparin Drugs 0.000 claims 4
- 229940006607 hirudin Drugs 0.000 claims 4
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims 4
- 239000003055 low molecular weight heparin Substances 0.000 claims 4
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 4
- 210000000651 myofibroblast Anatomy 0.000 claims 4
- 230000002947 procoagulating effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 102000018317 Keratin-19 Human genes 0.000 claims 2
- 108010066302 Keratin-19 Proteins 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000001732 thrombotic effect Effects 0.000 claims 2
- 102000007469 Actins Human genes 0.000 claims 1
- 108010085238 Actins Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 239000006285 cell suspension Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 210000005009 osteogenic cell Anatomy 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11152119 | 2011-01-25 | ||
| EP11152119.1 | 2011-01-25 | ||
| PCT/EP2012/051157 WO2012101181A1 (en) | 2011-01-25 | 2012-01-25 | Compositions and methods for cell transplantation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014508138A JP2014508138A (ja) | 2014-04-03 |
| JP2014508138A5 true JP2014508138A5 (enExample) | 2015-03-12 |
| JP6012629B2 JP6012629B2 (ja) | 2016-10-25 |
Family
ID=45607724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549850A Expired - Fee Related JP6012629B2 (ja) | 2011-01-25 | 2012-01-25 | 細胞移植のための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20130302291A1 (enExample) |
| EP (1) | EP2667878B1 (enExample) |
| JP (1) | JP6012629B2 (enExample) |
| CN (1) | CN103402527B (enExample) |
| CA (1) | CA2825252C (enExample) |
| DK (1) | DK2667878T3 (enExample) |
| ES (1) | ES2573522T3 (enExample) |
| IL (1) | IL227529A0 (enExample) |
| PL (1) | PL2667878T3 (enExample) |
| PT (1) | PT2667878E (enExample) |
| SG (1) | SG192124A1 (enExample) |
| WO (1) | WO2012101181A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013110354A1 (en) | 2012-01-25 | 2013-08-01 | Université Catholique de Louvain | Compositions and methods for cell transplantation |
| CA2825252C (en) | 2011-01-25 | 2018-10-16 | Universite Catholique De Louvain | Compositions of an antithrombin activator and a thrombin inhibitor for use in cell transplantation |
| CN105142650B (zh) * | 2013-01-12 | 2019-08-27 | 西斯卡治疗学有限公司 | 自体骨髓源性干细胞的快速输注 |
| ES2831756T3 (es) * | 2013-03-15 | 2021-06-09 | Miromatrix Medical Inc | Uso de hígado descelularizado por perfusión para la recelularización de células de islotes |
| DK3016665T3 (da) | 2013-07-05 | 2019-11-25 | Univ Catholique Louvain | Konditioneret medium fra humane voksne leverstamceller og dets anvendelse i behandlingen af leverlidelser |
| BR102013033827B1 (pt) * | 2013-12-27 | 2021-09-08 | Regenera - Medicina Veterinária Avançada Ltda. | Concentrado multipotente e imunocompatível de células-tronco e biofármaco e forma de dosagem que o compreendem |
| JP6887628B2 (ja) * | 2015-06-11 | 2021-06-16 | ユニフェルシテイト マーストリヒトＵｎｉｖｅｒｓｉｔｅｉｔ Ｍａａｓｔｒｉｃｈｔ | 被移植体における移植不全を防ぐ方法 |
| CN106995796A (zh) * | 2016-01-26 | 2017-08-01 | 李建业 | 基于细胞因子的细胞处理方法、试剂盒及冻干粉 |
| CN110177871B (zh) * | 2017-03-03 | 2023-05-09 | 日本乐敦制药株式会社 | 间充质干细胞和肝疾病治疗剂 |
| BR112019026444A2 (pt) * | 2017-06-12 | 2020-07-14 | The University Of North Carolina At Chapel Hill | composições de enxerto tipo patch graft para enxerto celular |
| JP7264589B2 (ja) * | 2017-12-25 | 2023-04-25 | 株式会社 資生堂 | トロンビンの抑制作用を指標とした皮膚状態改善剤のスクリーニング方法、及びトロンビン作用阻害剤を含む皮膚状態改善剤 |
| WO2019241499A1 (en) | 2018-06-13 | 2019-12-19 | Miromatrix Medical Inc. | Fistula filler and deployment system |
| KR20220004977A (ko) * | 2019-03-26 | 2022-01-12 | 프로메테라 테라푸틱스 에스에이 | 만성 간부전의 급성 악화를 치료하기 위한 성체 간 전구 세포 |
| CN112608890B (zh) * | 2020-12-17 | 2024-08-20 | 山东佰鸿干细胞生物技术有限公司 | 一种防止间充质干细胞粘连的培养方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9010552D0 (en) | 1990-05-10 | 1990-07-04 | Erba Carlo Spa | Method for the recombinant production of hirudins and novel hirudins |
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5837539A (en) | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
| US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
| US5827740A (en) | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
| GB0014136D0 (en) | 2000-06-10 | 2000-08-02 | Astrazeneca Ab | Combination therapy |
| DE10202982A1 (de) | 2002-01-26 | 2003-07-31 | Augustinus Bader | Verfahren und Vorrichtung zum Einbringen von lebenden Zellen in eine biologische Körperflüssigkeit |
| US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
| WO2006126219A1 (en) | 2005-05-26 | 2006-11-30 | Fresenius Medical Care Deutschland G.M.B.H. | Liver progenitor cells |
| EP1996013A4 (en) | 2005-09-21 | 2010-03-10 | Dask Technologies Llc | METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES |
| WO2007071339A1 (en) * | 2005-12-21 | 2007-06-28 | Universite Catholique De Louvain | Isolated liver stem cells |
| WO2013110354A1 (en) | 2012-01-25 | 2013-08-01 | Université Catholique de Louvain | Compositions and methods for cell transplantation |
| CA2825252C (en) | 2011-01-25 | 2018-10-16 | Universite Catholique De Louvain | Compositions of an antithrombin activator and a thrombin inhibitor for use in cell transplantation |
-
2012
- 2012-01-25 CA CA2825252A patent/CA2825252C/en not_active Expired - Fee Related
- 2012-01-25 PL PL12704242.2T patent/PL2667878T3/pl unknown
- 2012-01-25 EP EP12704242.2A patent/EP2667878B1/en not_active Not-in-force
- 2012-01-25 ES ES12704242.2T patent/ES2573522T3/es active Active
- 2012-01-25 SG SG2013056510A patent/SG192124A1/en unknown
- 2012-01-25 CN CN201280011169.6A patent/CN103402527B/zh not_active Expired - Fee Related
- 2012-01-25 DK DK12704242.2T patent/DK2667878T3/en active
- 2012-01-25 PT PT127042422T patent/PT2667878E/pt unknown
- 2012-01-25 JP JP2013549850A patent/JP6012629B2/ja not_active Expired - Fee Related
- 2012-01-25 US US13/981,720 patent/US20130302291A1/en not_active Abandoned
- 2012-01-25 WO PCT/EP2012/051157 patent/WO2012101181A1/en not_active Ceased
-
2013
- 2013-07-18 IL IL227529A patent/IL227529A0/en active IP Right Grant
-
2016
- 2016-10-06 US US15/287,061 patent/US10039789B2/en not_active Expired - Fee Related
-
2017
- 2017-08-25 US US15/687,340 patent/US10478459B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014508138A5 (enExample) | ||
| JP2015508054A5 (enExample) | ||
| Sang et al. | Intraportal mesenchymal stem cell transplantation prevents acute liver failure through promoting cell proliferation and inhibiting apoptosis | |
| WO2009033731A3 (en) | Use of a laminin peptide as a therapeutic agent | |
| WO2009033774A3 (en) | Use of a laminin nonapeptide as a therapeutic agent | |
| WO2009043464A3 (en) | Astressin and beta- endorphin for use as therapeutic agents | |
| Slegtenhorst et al. | Mechanisms and consequences of injury and repair in older organ transplants | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| BR112014012739A2 (pt) | composições e métodos para o tratamento do vírus da hepatite c | |
| WO2009033711A3 (en) | Use of glp-1 as a therapeutic agent | |
| WO2009033799A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033756A3 (en) | Use of oxyntomodulin alone or in combination with melanotropin potentiating factor as a therapeutic agent | |
| WO2009033717A3 (en) | Use of gonadorelin as a therapeutic agent | |
| WO2009040084A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033789A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009040083A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033730A3 (en) | Peptide gxgrgdspca as a therapeutic agent | |
| WO2009033760A3 (en) | Use of fibronectin fragment (196-203 ) as a therapeutic agent | |
| WO2009046845A3 (en) | Use of a lactoferrin partial peptide peptide as a therapeutic agent | |
| Tombor et al. | Why is endothelial resilience key to maintain cardiac health? | |
| NZ718514A (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| WO2009043456A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033714A3 (en) | Use of a peptide as a therapeutic agent | |
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| Chen et al. | Exosomes derived from human umbilical cord mesenchymal stem cells protect against papain-induced emphysema by preventing apoptosis through activating VEGF-VEGFR2-mediated AKT and MEK/ERK pathways in rats |